REGISTRATION FEETitle of Each Class ofSecurities to be RegisteredProposedMaximumAggregateOffering Price(1)(2)Amount ofRegistration Fee(3)Common stock, $0.01 par value per share$165,211,875$20,569(1)Includes additional shares of common stock that the underwriters have the option to purchase.(2)Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended.(3)A registration fee of $13,912 was previously paid in connection with the Registration Statement.
of $38.31 per share, the last reported sale price of our common stock on The Nasdaq Global Select Market on June 4, 2018, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, as follows:•approximately $75 million to fund clinical trials forDCC-2618,including the dose escalation and expansion stages of our current Phase 1 clinical trial, a pivotal
manufacturing of clinical trial material;•approximately $9 million to fund clinical trials for rebastinib, as well as clinical research outsourcing and manufacturing of clinical trial material;•approximately $10 million to fund new and ongoing research activities for future drug candidates using our proprietary kinase switch control inhibitor platform; and•the remainder for working capital purposes, including general operating expenses.See “Use of Proceeds” for additional information.Risk factorsSee “Risk Factors” beginning on page 18 and the other information included in, or incorporated by reference into, this prospectus for a discussion of factors you should carefully consider before deciding to invest in our common
Nasdaq Global Select Market on June 4, 2018, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.A $1.00 increase (decrease) in the assumed public offering price of $38.31 per share, the last reported sale price of our common stock on The
will be influenced by a number of factors, including:•the issuance of new equity securities pursuant to this offering or a future offering, including issuances of preferred stock;•changes in interest rates;•significant dilution caused by the anti-dilutive clauses in our financial agreements;•competitive developments, including announcements by competitors of new products or services or significant contracts, acquisitions, strategic partnerships, joint ventures or capital commitments;•variations in quarterly operating results;•change in financial estimates by securities analysts;•the depth and liquidity of the market for our common stock;•investor perceptions of our company and the pharmaceutical and biotech industries generally; and•general economic and other national conditions.The price of our common stock may be volatile and
The market price for our common stock may be influenced by many factors, including:•the degree of success of competitive products or technologies;•results of clinical trials and preclinical studies, of our drug candidates or those of our competitors;•regulatory or legal developments in the United States and other countries;•receipt of, or failure to obtain, regulatory approvals;•developments or disputes concerning patent applications, issued patents or other proprietary rights;•the recruitment or departure of key personnel;•the level of expenses related to any of our drug candidates or clinical development programs;•the results of our efforts to discover, develop, acquire or in-license additional technologies or drug candidates;•actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;•variations in our financial results or those of companies that are perceived to be similar to us;•rumors or announcements regarding transactions involving our company or drug candidates;•changes in the structure of healthcare payment systems;•market conditions in the pharmaceutical and biotechnology sectors;•general economic, industry and market conditions; and•the other factors described or incorporated by reference in this “Risk Factors” section.We
stock have rights, subject to specified conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders.21Table of ContentsSPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTSThis prospectus and the documents incorporated by reference contain forward-looking statements, which reflect our current views with respect
candidate;•our expectations regarding the size of target patient populations for our drug candidates, if approved for commercial use, and any additional drug candidates we may develop;•our ability to obtain funding for our operations;•our ability to manufacture sufficient quantities of DCC-2618 to support our planned clinical trials and, if approved, commercialization;•the commercialization of our drug candidates, if approved;•our plans to research, develop and commercialize our drug candidates, including the timing of our second planned Phase 3 trial for DCC-2618 in GIST;•our ability to attract collaborators with development, regulatory and commercialization expertise;•our expectations regarding our ability to obtain, maintain, enforce and defend our intellectual property protection for our drug candidates;•future agreements with third parties in connection with the commercialization of DCC-2618, or any of our other current or future drug candidates;•the size and growth potential of the markets for our drug candidates, and our ability to serve those markets;•the rate and degree of market acceptance of our drug candidates, as well as the reimbursement coverage for our drug candidates;•regulatory and legal developments in the United States and foreign countries;•the performance of our third-party suppliers and manufacturers;•the success of competing therapies that are or may become available;•our ability to attract and retain key scientific or management personnel;•the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing;22Table of Contents•our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act; and•our use of the proceeds from our IPO.These factors should not be construed as exhaustive and
$134.3 million, based on an assumed public offering price of $38.31 per share, the last reported sale price of our common stock on The Nasdaq Global Select Market on June 4, 2018, and after deducting estimated underwriting discounts and
requirements, general business conditions and other factors that our board of directors may deem relevant.27Table of ContentsCAPITALIZATIONThe following table sets forth our cash and cash equivalents and our capitalization as of March 31, 2018:•on an actual basis; and•on an as adjusted basis to give effect to the sale by us of 3,750,000 shares of our common stock in this offering at an assumed public offering price of $38.31 per share, the last reported sale price of our common